Targets › P2Y12
1 program from 1 company in 1 trial: 1 Phase 2; Neurology.
Open in Phaseline: the race on P2Y12, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tianjin Institute of Pharmaceutical Research Co., Ltd | Tiprogrel P2Y12 receptor antagonist | P2Y12 | Phase 2 | Ischemic Stroke | – |
Ischemic Stroke (1)
small molecule (1)
Tianjin Institute of Pharmaceutical Research Co., Ltd (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.